MaxCyte, Inc. Accretion (Amortization) of Discounts and Premiums, Investments
MaxCyte, Inc. (MXCT) reported Accretion (Amortization) of Discounts and Premiums, Investments of $838.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-13
- MaxCyte, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-06-30 was $401.00K, a 46.60% decline year-over-year.
- MaxCyte, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-03-31 was $437.00K, a 50.57% decline year-over-year.
- MaxCyte, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-12-31 was $427.00K, a 64.12% decline year-over-year.
- MaxCyte, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-09-30 was $584.00K, a 57.89% decline year-over-year.
- MaxCyte, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $2.65M, a 57.61% decline from fiscal 2024.
- MaxCyte, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $6.24M, a 12.33% decline from fiscal 2023.
- MaxCyte, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $7.12M, a 166.97% increase from fiscal 2022.
- MaxCyte, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2022 was $2.67M, a 3693.74% increase from fiscal 2021.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 3 month as first filed | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month as first filed | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month as first filed | Accretion (Amortization) of Discounts and Premiums, Investments 12 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $401.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $838.00K 10-Q · filed 2026-08-13 | $1.26M derived: sum of 3 quarters · filed 2026-08-13 | $1.85M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $437.00K 10-Q · filed 2026-05-13 | $864.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.45M derived: sum of 3 quarters · filed 2026-05-13 | $2.20M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.01M derived: sum of 2 quarters · filed 2026-03-25 | $1.76M derived: sum of 3 quarters · filed 2026-08-13 | $2.65M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $584.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.33M derived: sum of 2 quarters · filed 2026-08-13 | $2.22M 10-Q · filed 2025-11-13 | $3.41M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $751.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.64M 10-Q · filed 2026-08-13 | $2.83M derived: sum of 3 quarters · filed 2026-08-13 | $4.21M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $884.00K 10-Q · filed 2026-05-13 | $2.07M derived: sum of 2 quarters · filed 2026-05-13 | $3.46M derived: sum of 3 quarters · filed 2026-05-13 | $5.14M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.58M derived: sum of 2 quarters · filed 2026-03-25 | $4.26M derived: sum of 3 quarters · filed 2026-03-25 | $6.24M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.07M derived: sum of 2 quarters · filed 2025-11-13 | $5.05M 10-Q · filed 2025-11-13 | $7.05M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.67M 10-Q · filed 2025-08-06 | $5.66M derived: sum of 3 quarters · filed 2025-08-06 | $7.14M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $1.98M 10-Q · filed 2025-05-08 | $3.98M derived: sum of 2 quarters · filed 2025-05-08 | $5.46M derived: sum of 3 quarters · filed 2025-05-08 | $7.37M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.48M derived: sum of 2 quarters · filed 2025-03-11 | $5.39M derived: sum of 3 quarters · filed 2025-03-11 | $7.12M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $3.39M derived: sum of 2 quarters · filed 2024-11-06 | $5.12M 10-Q · filed 2024-11-06 | $5.12M 10-Q · filed 2023-11-08 | $6.63M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.64M 10-Q · filed 2024-08-06 | $3.64M 10-Q · filed 2023-08-09 | $5.15M derived: sum of 3 quarters · filed 2024-08-06 | $6.10M derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | $1.73M 10-Q · filed 2024-05-07 | $1.73M 10-Q · filed 2023-05-10 | $3.24M derived: sum of 2 quarters · filed 2024-05-07 | $4.19M derived: sum of 3 quarters · filed 2024-05-07 | $4.36M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.46M derived: sum of 2 quarters · filed 2024-03-12 | $2.63M derived: sum of 3 quarters · filed 2024-03-12 | $2.67M 10-K · filed 2024-03-12 | $2.67M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $952.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.13M derived: sum of 2 quarters · filed 2023-11-08 | $1.16M 10-Q · filed 2023-11-08 | $1.19M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $172.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $206.10K 10-Q · filed 2023-08-09 | $236.90K derived: sum of 3 quarters · filed 2023-08-09 | $278.30K derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $33.20K 10-Q · filed 2023-05-10 | $64.00K derived: sum of 2 quarters · filed 2023-05-10 | $105.40K derived: sum of 3 quarters · filed 2023-05-10 | $111.00K derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $30.80K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $72.20K derived: sum of 2 quarters · filed 2023-03-15 | $77.80K derived: sum of 3 quarters · filed 2023-03-15 | $70.30K 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $41.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $47.00K derived: sum of 2 quarters · filed 2022-11-09 | $39.50K 10-Q · filed 2022-11-09 | $38.00K derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $5.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$1.90K 10-Q · filed 2022-08-10 | -$3.40K derived: sum of 3 quarters · filed 2022-08-10 | $800.00 derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$7.50K 10-Q · filed 2022-05-09 | -$9.00K derived: sum of 2 quarters · filed 2022-05-09 | -$4.80K derived: sum of 3 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | -$1.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $2.70K derived: sum of 2 quarters · filed 2022-03-22 | $3.80K 10-K · filed 2022-03-22 | |||||
| 2020-09-30 | $4.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $5.30K 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $1.10K 10-Q · filed 2021-09-13 | |||||||
| 2019-12-31 | $32.60K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |